Side Effects of simeprevir: A Synthesis of Findings from 29 Studies

  1. Home
  2. Side Effects of simeprevir
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of simeprevir: A Synthesis of Findings from 29 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of simeprevir: A Synthesis of Findings from 29 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Sofosbuvir-containing regimens have been shown to achieve high sustained virological response (SVR) rates in patients with hepatitis C virus (HCV) with or without human immunodeficiency virus (HIV) in clinical trials. 23

For liver transplant recipients with HCV and HIV co-infection, recurrence after LT is associated with a higher risk of graft loss than for HCV mono-infected patients. 20

Chronic hepatitis C virus (HCV) infection causes significant mortality in patients with inherited bleeding disorders, however, data of interferon-free antiviral regimes are scarce in this population. 16

Direct-acting antivirals (DAAs) are an emerging group of small molecule inhibitors that effectively treat hepatitis C virus (HCV) infection, a common comorbidity in end-stage renal disease patients. 29

Simeprevir plus sofosbuvir (SIM/SOF) regimen was recommended by professional guidelines for certain patients with HCV genotype 1 infection and there is lack of data about this regimen in patients with genotype 4 infection. 14

Recurrence of hepatitis C virus (HCV)-associated membranoproliferative glomerulonephritis (MPGN) in the kidney transplant may lead to continuous graft deterioration and the need for further renal replacement therapy. 12

Hepatitis C virus (HCV) infection and its treatments are associated with significant symptoms, side effects and impact on patients functioning. 2

Hepatitis C (HC) is a very relevant negative prognosis factor for graft and transplant recipient survival. 9

Direct-acting anti-virals (DAAs) licensed to treat chronic HCV infection have revolutionised treatment algorithms by drastically mitigating side effects while enhancing efficacy relative to interferon-based therapy. 28

The COSMOS study was a phase 2a clinical trial that showed high cure rates of genotype 1 chronic hepatitis C (CHC) and a favorable side effect profile using a 12-week regimen of simeprevir + sofosbuvir (SIM + SOF). 21

Outcome data on simeprevir and sofosbuvir (SMV+SOF) in patients with liver transplantation (LT) with hepatitis C virus genotype 1 (HCV-1) are limited with individual studies having a small sample size and limited SVR12 (sustained virological response) data. 22

There are few data on the real-world experience of FDA-approved oral hepatitis C virus (HCV) direct-acting antiviral (DAA) drug combinations in HIV/HCV-coinfected patients. 18

To investigate the long-term effects and safety of new direct anti-viral agents (DAAs) in patients with hepatitis C virus (HCV)-related mixed cryoglobulinaemia (MC) without renal involvement. 5

Over the last years it has started a real revolution in the treatment of chronic hepatitis C. 27

The combination of sofosbuvir and simeprevir ± ribavirin (SOF + SMV ± RBV) for hepatitis C virus (HCV) treatment has been associated with high rates of sustained virological response (SVR). 8

Since 2014 several direct-acting antivirals (DAAs) have been made available, allowing interferon-free antiviral treatments with high sustained virological response rates. 19

There have been no previous reports on the use of interferon-free combinations in pediatric patients with chronic hepatitis C infection. 24

Direct acting antiviral has offered treatment of hepatitis C virus (HCV) recurrence post liver transplantation (LT) with an all-oral regimen for short duration, excellent safety profile, and high sustained virological response (SVR). 3

Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). 13

Approximately three million individuals in the United States are chronically infected with hepatitis C virus (HCV). 10

Treatment of chronic hepatitis C (HCV) with newer direct acting antiviral (DAA) agents has been highly effective. 7

Interferon and ribavirin-free regimens to treat chronic hepatitis C virus (HCV) infection in patients with end stage renal disease are not approved and represent an area of unmet clinical need. 26

Hepatitis C is one of the commonest public health problems with 130 million people infected worldwide and the burden is increasing. 8

Due to the intimate relationship between liver and kidney disease in hepatitis C virus (HCV) infection, treatment options for HCV-positive patients at any stage of chronic kidney disease (CKD) are essential. 25

Hepatitis C virus (HCV) infection is a major worldwide problem that has emerged as one of the most significant diseases affecting humans. 6

Interferon-free regimens are associated with high sustained virological response; however, associated adverse effects have yet to be fully reported. 4

The prevalence of Hepatitis C Virus (HCV) infection is significantly higher in patients with end-stage renal disease compared to the general population and poses important clinical challenges in patients who undergo kidney transplantation. 17

Direct-acting antivirals (DAAs) against Hepatitis C virus (HCV) show effective antiviral activity with few side effects. 15

We evaluated the safety and side effects of sildenafil in a group of sexually active volunteers younger than 40 years under conditions without sexual stimulation. 1

Reasons for Side Effects

The reasons for side effects of simeprevir can vary, including pharmacological action and individual constitution. Please refer to the papers for more details.

Common Side Effects

Rash

Rash and pruritus have been reported in patients receiving simeprevir treatment. 22 8

Fatigue

Fatigue has been reported in patients receiving simeprevir treatment. 8

Anemia

Anemia has been reported in patients receiving simeprevir treatment. 8

Dyspepsia

Dyspepsia has been reported in patients receiving simeprevir treatment. 1

Headache

Headache has been reported in patients receiving simeprevir treatment. 1 8

Palpitation

Palpitation has been reported in patients receiving simeprevir treatment. 1

Arthralgia

Arthralgia has been reported in patients receiving simeprevir treatment. 1

Neurotoxicity

Neurotoxicity has been reported in patients receiving simeprevir treatment. 9

Side Effects Management

Rash

If you experience a rash, consult your doctor. If the symptoms are severe, you may need to stop treatment.

Fatigue

If you experience fatigue, get enough rest and avoid overexertion. If the symptoms are severe, consult your doctor.

Anemia

If you experience anemia, consult your doctor. You may need to receive treatment such as iron supplements if necessary.

Dyspepsia

If you experience dyspepsia, be careful about your diet and eat easily digestible foods. If the symptoms are severe, consult your doctor.

Headache

If you experience a headache, take over-the-counter pain relievers or rest. If the symptoms are severe, consult your doctor.

Palpitation

If you experience palpitations, calm down by taking deep breaths. If the symptoms are severe, consult your doctor.

Arthralgia

If you experience arthralgia, rest. If the symptoms are severe, consult your doctor.

Neurotoxicity

If you experience symptoms of neurotoxicity, consult your doctor immediately. You may need to stop treatment.

Comparison Between Studies

Similarities in Studies

Many studies have shown that simeprevir treatment is effective. It is also common that simeprevir treatment may be accompanied by side effects.

Differences in Studies

The effects and incidence of side effects of simeprevir may differ depending on the study. This may be due to differences in the patient population and treatment methods studied.

Precautions for Real-Life Applications

Simeprevir is an effective treatment for hepatitis C, but there is a risk of side effects. When receiving simeprevir treatment, it is important to consult your doctor and choose a treatment method that suits your situation. Also, during treatment, be sure to undergo regular examinations as instructed by your doctor.

Limitations of Current Research

Research on simeprevir is still insufficient. In particular, data on long-term effects are lacking.

Future Research Directions

Research on the long-term effects and safety of simeprevir is needed in the future.

Conclusion

Simeprevir is an effective treatment for hepatitis C, but there is a risk of side effects. When receiving simeprevir treatment, it is important to consult your doctor and choose a treatment method that suits your situation. Also, during treatment, be sure to undergo regular examinations as instructed by your doctor. Future research is expected to further elucidate information on the safety and efficacy of simeprevir.

Literature analysis of 29 papers
Positive Content
28
Neutral Content
1
Negative Content
0
Article Type
1
0
0
5
28
1.

Evaluation of side effects of sildenafil in group of young healthy volunteers.

Author: DündarM, KoçakI, DündarS O, ErolH

Treat erectile dysfunction
Arthralgia
Dyspepsia
Flushing
Headache
Palpitation

Sildenafil, a drug for erectile dysfunction, showed a statistically significant increase in heart rate and common side effects like flushing, headache, and dyspepsia in sexually active volunteers, even without sexual stimulation. While these side effects may be acceptable, potential users should be informed of their likelihood.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.

Author: YosryAyman, Gamal EldeenHadeel, MedhatEman, MehrezMai, ZayedNaglaa, ElakelWafaa, AbdelmoniemReham, KaddahMona, AbdelazizAshraf, EsmatGamal, El-SerafyMagdy, DossWahid

HCV recurrence treatment

Sofosbuvir-based regimens are effective and safe for treating recurrent HCV post-liver transplantation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients.

Author: AttiaD, El SaeedK, ElakelW, El BazT, OmarA, YosryA, ElsayedM H, SaidM, El RazikyM, AneesM, DossW, El ShazlyY, WedemeyerH, EsmatG

High sustained virological response
Anaemia
Hepatocellular carcinoma
Hyperbilirubinemia
Mortality

Direct-acting antiviral drug regimens for hepatitis C were associated with adverse effects, with anemia being the most common. Sofosbuvir/ribavirin had the highest rate of side effects, while sofosbuvir/daclatasvir had the lowest.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

5.

Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.

Author: MazzaroCesare, Dal MasoLuigino, QuartuccioLuca, GhersettiMichela, LenziMarco, MauroEndri, BondMilena, CasarinPietro, GatteiValter, CrosatoIvo Maria, De VitaSalvatore, PozzatoGabriele

Clinical response in vasculitis
HCV eradication
Ribavirin-related anemia

Direct-acting antiviral therapy effectively eradicated hepatitis C in patients with mixed cryoglobulinemia without renal involvement. While it showed satisfactory clinical response in mild to moderate cryoglobulinemic vasculitis, it did not affect B-cell non-Hodgkin lymphoma.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

6.

Chemical genetics-based development of small molecules targeting hepatitis C virus.

Author: JinGuanghai, LeeJisu, LeeKyeong

DAAs effective
HCV treatment
HCV infection

This review discusses the development of new drugs for the treatment of hepatitis C virus (HCV) infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.

Author: BrunoGiuseppe, SaracinoAnnalisa, FabrizioClaudia, ScudellerLuigia, MilanoEugenio, Dell'AcquaRaffaele, LadisaNicoletta, FasanoMassimo, MinnitiSalvatore, BuccolieroGiovanni, TartagliaAlessandra, GiammarioAdele, MilellaMichele, AngaranoGioacchino

High SVR rate
Safe treatment

This study evaluated the efficacy and safety of a 12-week treatment regimen of sofosbuvir, simeprevir, and ribavirin for hepatitis C virus (HCV) infection in both HCV monoinfected and HIV/HCV co-infected individuals. The study found that this regimen achieved high rates of sustained virological response (SVR) in both groups, demonstrating its effectiveness in treating HCV infection, particularly in patients with co-infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

9.

Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.

Author: GentilM A, González-CorvilloC, PerellóM, ZarragaS, Jiménez-MartínC, LauzuricaL R, AlonsoA, FrancoA, Hernández-MarreroD, Sánchez-FructuosoA

Hepatitis C treatment
Improved liver function
Improved prognosis
Anemia
Neurotoxicity

Direct-acting antiviral agents (DAAs) are very effective in treating Hepatitis C in kidney transplant recipients, with a 97.8% virological response rate. DAAs were well tolerated with limited side effects, except in 7 patients who had to stop treatment due to neurotoxicity or anemia. The use of DAAs in kidney transplant recipients requires special coordination with digestive professionals.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

10.

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.

Author: LawitzE, PoordadF, GutierrezJ A, KakudaT N, PicchioG, BeetsG, VandevoordeA, Van RemoortereP, JacquemynB, LuoD, Ouwerkerk-MahadevanS, VijgenL, Van EygenV, BeumontM

Effective HCV treatment
Well tolerated
Gastrointestinal hemorrhage

This study assessed the efficacy and safety of a combination of three direct-acting antivirals (simeprevir, daclatasvir, and sofosbuvir) in HCV genotype 1- or 4-infected cirrhotic patients with portal hypertension or decompensated liver disease. The combination therapy was found to be safe and well-tolerated, resulting in sustained virologic response (SVR12) in all 40 patients.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

New Direct Acting Antiviral Agents for the Treatment of Hepatitis C: 2016 and Beyond.

Author: UmarMuhammad, AkhterTayyab Saeed

Hepatitis C treatment
Side effects

This article reviews the persistently changing treatment regimens for hepatitis C and simplifies the dynamicity of the subject and selection of appropriate regimens for patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis.

Author: SchrezenmeierE, WuK, HalleckF, LiefeldtL, BrakemeierS, BachmannF, KronS, BuddeK, DuerrM

HCV treatment
MPGN treatment

Direct-acting antiviral agents (DAAs) are effective for treating hepatitis C. This study presents a case report of a patient with recurrent HCV-associated membranoproliferative glomerulonephritis in a kidney transplant who experienced successful recovery after DAA treatment.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

13.

Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.

Author: DumortierJérôme, BaillyFrançois, PageauxGeorges-Philippe, Vallet-PichardAnaïs, RadenneSylvie, HabersetzerFrançois, GagnieuMarie-Claude, GrangéJean-Didier, MinelloAnne, GuillaudOlivier, KamarNassim, AlricLaurent, LeroyVincent

Effective treatment for HCV

Sofosbuvir (SOF) is a direct-acting antiviral used to treat hepatitis C, which is common in patients with end-stage renal disease. This study investigated the efficacy and safety of SOF in HCV-infected patients with severe renal failure, including those on hemodialysis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

14.

Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.

Author: El-KhayatHisham R, FouadYasser M, MaherMohsen, El-AminHussain, MuhammedHala

HCV genotype 4 treatment
Hyperbilirubinemia
Photosensitivity
Pruritus
Rash

A 12-week regimen of simeprevir/sofosbuvir was effective and well tolerated in patients with chronic HCV genotype 4 infection, regardless of prior treatment experience. The SVR12 rate was 95.7%. Common side effects included rash, photosensitivity, pruritus, and hyperbilirubinemia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

15.

Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems.

Author: LiuFanwei, ShimakamiTetsuro, MuraiKazuhisa, ShirasakiTakayoshi, FunakiMasaya, HondaMasao, MurakamiSeishi, YiMinkyung, TangHong, KanekoShuichi

Hepatitis C treatment

This study evaluated the combination of direct-acting antivirals (DAAs) with anti-miR-122 treatment for Hepatitis C virus (HCV) infection. The combination showed additive or synergistic antiviral effects and was more effective at suppressing HCV replication and preventing the emergence of DAA-resistant mutants than DAAs alone.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders.

Author: WiegandJohannes, SchiefkeIngolf, SteinKerstin, BergThomas, KulligUlrike, EndeKatrin

HCV treatment

Interferon-free therapies are effective and safe in treating patients with inherited bleeding disorders and chronic HCV genotype 1 infection.

Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.

Author: LinMing V, SiseMeghan E, PavlakisMartha, AmundsenBeth M, ChuteDonald, RutherfordAnna E, ChungRaymond T, CurryMichael P, HanifiJasmine M, GabardiSteve, ChandrakerAnil, HeherEliot C, EliasNahel, RiellaLeonardo V

HCV treatment
Adverse events

All-oral, interferon-free direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection were found to be safe and effective in patients who had received kidney transplants. The overall sustained virologic response rate was 91%, highlighting the potential for improved treatment outcomes in this patient population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

18.

High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.

Author: HawkinsClaudia, GrantJennifer, AmmermanLauren Rose, PalellaFrank, MclaughlinMilena, GreenRichard, McgregorDonna, StosorValentina

Effective HCV treatment
Well-tolerated

Direct-acting antiviral (DAA) drug combinations were highly effective and well tolerated in HIV/HCV-coinfected patients. The SVR12 rate was 92% in patients who completed therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

19.

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.

Author: IzzoIlaria, ZanottiPaola, ChiricoClaudia, CasariSalvatore, VillanacciVincenzo, SalemmeMarianna, BiasiLuciano, FestaElena, CastelliFrancesco

Treat hepatitis C
Drug-induced colitis

This case report describes a patient who developed significant bloody diarrhea within 3 weeks of initiating sofosbuvir/simeprevir/ribavirin treatment for genotype 1 hepatitis C. Colonoscopy and biopsy suggested a drug-induced colitis. This highlights the need for close monitoring for side effects, including colitis, during DAA treatment for hepatitis C.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.

Author: Campos-VarelaI, MorenoA, MorbeyA, GuaraldiG, HassonH, BhamidimarriK R, CastellsL, GrewalP, BañosI, BellotP, BrainardD M, McHutchisonJ G, TerraultN A

Treatment of HCV and HIV co-infection
Graft loss

The study highlights the challenges of treating hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection in liver transplant recipients due to the higher risk of graft loss.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.

Author: NguyenNghia H, YeeBrittany E, ChangChristine, JinMinjuan, LutchmanGlen, LimJoseph K, NguyenMindie H

Improved outcome
Sustained virological response

This meta-analysis evaluated the efficacy and safety of simeprevir and sofosbuvir (SMV+SOF) with or without ribavirin (RBV) for hepatitis C virus genotype 1 (HCV-1) infection in liver transplant (LT) recipients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

23.

Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.

Author: Del BelloDavid, ChaAgnes, SorberaMaria, BichoupanKian, LevineCalley, DoyleErin, HartyAlyson, PatelNeal, NgMichel, GardenierDonald, OdinJoseph, SchianoThomas D, FiererDaniel S, BerkowitzLeonard, PerumalswamiPonni V, DieterichDouglas T, BranchAndrea D

HCV treatment

This study looked at the effectiveness of sofosbuvir-based regimens for treating hepatitis C virus (HCV) in patients who also have HIV. While clinical trials have shown high cure rates, real-world data on this combination is still needed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

24.

Sofosbuvir and Simeprevir Treatment of a Stem Cell Transplanted Teenager With Chronic Hepatitis C Infection.

Author: FischlerBjörn, PriftakisPeter, SundinMikael

Hepatitis C treatment
Peripheral edema

This study reports a case of a pediatric patient with chronic hepatitis C infection who successfully completed treatment with sofosbuvir and simeprevir, a combination that does not include interferon, despite ongoing immunosuppression.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.

Author: SorberaMaria A, FriedmanMichelle L, CopeRebecca

Treatment for HCV in CKD

Direct-acting antiviral (DAA) combinations are used to treat hepatitis C virus (HCV) infection. This article reviews the available literature on the use of second-generation DAAs in patients with chronic kidney disease (CKD).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

26.

Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.

Author: SinghTavankit, GuirguisJohn, AnthonySumi, RivasJohn, HanounehIbrahim A, AlkhouriNaim

Improved HCV treatment

Sofosbuvir/simeprevir and sofosbuvir/ledipasvir regimens have shown promising safety and efficacy in treating chronic hepatitis C virus infection in patients on hemodialysis, addressing a significant unmet clinical need for this patient population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

27.

Chronic hepatitis C: This and the new era of treatment.

Author: BertinoGaetano, ArdiriAnnalisa, ProitiMaria, RiganoGiuseppe, FrazzettoEvelise, DemmaShirin, RuggeriMaria Irene, ScuderiLaura, MalaguarneraGiulia, BertinoNicoletta, RapisardaVenerando, Di CarloIsidoro, ToroAdriana, SalomoneFederico, MalaguarneraMariano, BertinoEmanuele, MalaguarneraMichele

Improved HCV treatment

The development of direct-acting antiviral agents has significantly improved treatment outcomes for chronic hepatitis C, achieving sustained virologic response in approximately 90% of cases. Further advancements with pan-genotypic drugs are expected to provide even more effective and safe treatment options.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

28.

Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.

Author: BanerjeeD, ReddyK R

Disease management
HCV treatment
Accessibility
Resistance

DAAs are remarkably well tolerated, although they are accompanied by unique AEs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

29.

Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.

Author: SawinskiD, KaurN, AjetiA, Trofe-ClarkJ, LimM, BleicherM, GoralS, FordeK A, BloomR D

HCV treatment
Viral clearance
Well tolerated
Calcineurin inhibitor adjustment

Direct-acting antivirals (DAAs) effectively treat hepatitis C virus (HCV) infection, common in kidney transplant patients. This study demonstrates the feasibility and safety of DAA treatment in kidney transplant recipients with high success rates and minimal side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.